Matthieu Faron is an expert in Oncology at Institut Gustave Roussy (France). Matthieu Faron has authored 180 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 523 (community average: 125). How the SLR is computed.

LeadR Profile

Matthieu Faron Institut Gustave Roussy France
523 ScienceLeadR Reputation 523
Network Map

Oncology

Subspecialties: Surgery - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2016 - 2026

Source: PubMed

Gustave Roussy

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 180

Citations

Citations: 2 450 1st author: 21 Last author: 1 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.
PMID 42525308 — neoplasms, chondrosarcoma, drug therapy, therapeutics, chemotherapy
Curr Treat Options Oncol20260
Hepatic arterial embolization procedures in neuroendocrine tumors with carcinoid heart disease: a retrospective single-center study on safety and feasibility.
PMID 42439375 — heart diseases, safety, heart, neoplasms, liver, signs and symptoms, echocardiography, neuroendocrine tumors, carcinoid heart disease, carcinoid tumor
Endocr Relat Cancer20260
Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.
PMID 42134401 — registries, neoplasms, adrenocortical carcinoma, diagnosis
J Natl Compr Canc Netw20260
Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).
PMID 41862416 — mortality, lymph node excision, pancreaticoduodenectomy, multiple endocrine neoplasia type 1, neoplasms, cohort studies, multiple endocrine neoplasia, zollinger-ellison syndrome, lymph, gastrinoma, neuroectodermal tumors, primitive
World J Surg20260
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.
PMID 41313621 — neoplasms, multiple chronic conditions, sarcoma
Cancer Commun (Lond)20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
N/A 1
Phase 2 1

By status:

Completed 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
NCT07591493 — temozolomide, neoplasms, physical examination, chromogranins, drug therapy, biomarkers, hormones, signs and symptoms, chemotherapy, adjuvant, neuroendocrine tumors, chromogranin a, medical oncology, neuroectodermal tumors, primitive, capecitabine, chemotherapy
Phase 3Not yet recruiting2026

LeadR Networks

Main global connection map